keyword
MENU ▼
Read by QxMD icon Read
search

Pruritus, psoriasis

keyword
https://www.readbyqxmd.com/read/28419570/oral-lichenoid-reactions-associated-with-anti-pd-1-pd-l1-therapies-clinicopathological-findings
#1
V Sibaud, C Eid, V R Belum, P Combemale, B Barres, L Lamant, L Mourey, C Gomez-Roca, C L Estilo, R Motzer, E Vigarios, Mario E Lacouture
Immune checkpoint inhibitors targeting the programmed cell death receptor-1 (PD-1) or its ligand (PD-L1) show broad activity across different tumor types and currently represent one of the keystones of cancer management. Dermatologic toxicities are one of the most frequent immune-related adverse events (irAEs) induced by these new monoclonal antibodies. Maculopapular rash, pruritus, exacerbation of psoriasis or more specific autoimmune disorders (e.g. vitiligo, alopecia areata, and bullous pemphigoid) are amongst the most commonly reported AEs...
April 17, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28365081/a-possible-role-for-cd26-dppiv-enzyme-activity-in-the-regulation-of-psoriatic-pruritus
#2
Eriko Komiya, Ryo Hatano, Haruna Otsuka, Takumi Itoh, Hiroto Yamazaki, Taketo Yamada, Nam H Dang, Mitsutoshi Tominaga, Yasushi Suga, Utako Kimura, Kenji Takamori, Chikao Morimoto, Kei Ohnuma
BACKGROUND: Psoriasis (PSO) is one of the most common chronic inflammatory skin diseases, and pruritus affects approximately 60-90% of patients with PSO. However, the pathogenesis of pruritus in PSO remains unclear. Dipeptidyl peptidase IV (DPPIV) enzyme activity is involved in the regulation of peptide hormones, chemokines and neurotransmitters. OBJECTIVES: Our aim is to evaluate for a potential association between DPPIV and an increased risk of pruritus, and to identify possible underlying treatment targets in affected patients...
March 10, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28301619/two-multicenter-randomized-double-blind-parallel-group-comparison-studies-of-a-novel-enhanced-lotion-formulation-of-halobetasol-propionate-0-05-versus-its-vehicle-in-adult-subjects-with-plaque-psoriasis
#3
David Pariser, Michael Bukhalo, Scott Guenthner, Steven Kempers, Stephen Shideler, Linda Stein Gold, Eduardo Tschen, Jim Berg, Mary Beth Ferdon, Syd Dromgoole
<p>BACKGROUND: A novel lotion formulation of halobetasol propionate, 0.05% (HBP Lotion) with enhanced vehicle characteristics of a cream while preserving the ease of use and cosmetic elegance of a lotion has been developed to treat plaque psoriasis. OBJECTIVE: Determine the safety and effectiveness of HBP Lotion in patients with plaque psoriasis. METHODS: Two prospective, randomized, vehicle-controlled clinical studies were conducted in 443 adult subjects with moderate-severe plaque psoriasis...
March 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28294430/rapid-improvements-in-health-related-quality-of-life-and-itch-with-ixekizumab-treatment-in-randomized-phase-3-trials-results-from-uncover-2-and-uncover-3
#4
C L Leonardi, A Blauvelt, H L Sofen, M Gooderham, M Augustin, R Burge, B Zhu, K Reich
BACKGROUND: Patients with moderate-to-severe psoriasis report impaired health-related quality of life (HRQoL). OBJECTIVE: To assess speed of onset of ixekizumab-induced clinically relevant improvement in HRQoL. METHODS: This post-hoc analysis used pooled data from patients randomized in UNCOVER-2 and UNCOVER-3, and treated with 80 mg ixekizumab every 2 weeks (IXEQ2W), 80 mg ixekizumab every 4 weeks (IXEQ4W), 50 mg etanercept (ETN) twice weekly, or placebo (PBO) for 12 weeks...
March 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28290219/2-crisaborole-topical-ointment-for-the-treatment-of-mild-to-moderate-atopic-dermatitis
#5
Alice C Cheape, Dedee F Murrell
Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. Areas covered: So far, 7 trials have been completed in atopic dermatitis. The 2% strength appeared to be the superior dosing regimen. Pruritus improved significantly within one week. The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle...
April 5, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28289986/topical-botanical-agents-for-the-treatment-of-psoriasis-a-systematic-review
#6
REVIEW
Benjamin Farahnik, Divya Sharma, Joseph Alban, Raja K Sivamani
BACKGROUND: Patients with psoriasis often enquire about the use of numerous botanical therapeutics. It is important for dermatologists to be aware of the current evidence regarding these agents. METHODS: We conducted a systematic literature search using the PubMed, MEDLINE, and EMBASE databases for controlled and uncontrolled clinical trials that assessed the use of topical botanical therapeutics for psoriasis. The search included the following keywords: 'psoriasis' and 'plant' or 'herbal' or 'botanical'...
March 13, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28213862/apremilast-a-review-in-psoriasis-and-psoriatic-arthritis
#7
Gillian M Keating
Apremilast (Otezla(®)) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, including pruritus and the total Dermatology Life Quality Index, also improved to a significantly greater extent with apremilast than with placebo, with significant improvements in pruritus and skin discomfort/pain visual analogue scale scores seen as early as week 2 with apremilast...
March 2017: Drugs
https://www.readbyqxmd.com/read/28196317/common-skin-conditions-in-children-noninfectious-rashes
#8
Brian Z Rayala, Dean S Morrell
Cutaneous adverse drug reactions are among the most common noninfectious rashes of childhood. Cutaneous adverse drug reactions are classified as morbilliform, urticarial, bullous, pustular, or psoriasiform. Atopic dermatitis is one of the most common inflammatory cutaneous eruptions, and is characterized by pruritus and flexural distribution. Emollients and topical corticosteroids are first-line therapies. Topical calcineurin inhibitors are second-line, steroid-sparing drugs for certain conditions, such as face and eyelid eczema...
February 2017: FP Essentials
https://www.readbyqxmd.com/read/28124078/primary-biliary-cholangitis-associated-with-skin-disorders-a-case-report-and-review-of-the-literature
#9
REVIEW
Benedetta Terziroli Beretta-Piccoli, Caroline Guillod, Igor Marsteller, Roland Blum, Luca Mazzucchelli, Chiara Mondino, Pietro Invernizzi, M Eric Gershwin, Carlo Mainetti
Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease. It is often associated with extrahepatic autoimmune diseases. Skin disorders are sporadically reported in association with PBC. We report an unusual case of PBC associated with acquired reactive perforating dermatosis (ARPD) and present a review of the literature on skin disorders associated with PBC. Our patient presented to the dermatology department with generalized pruritus associated with nodular perforating skin lesions on the trunk, and cholestatic liver disease of unknown origin...
January 25, 2017: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/27943234/immune-related-alopecia-areata-and-universalis-type-in-cancer-patients-receiving-immune-checkpoint-inhibitors
#10
A Zarbo, V R Belum, V Sibaud, S Oudard, M A Postow, J J Hsieh, R J Motzer, K J Busam, M E Lacouture
CTLA-4, PD-1, and PD-L1 monoclonal antibodies, commonly known as immune checkpoint inhibitors, are used for the treatment of various malignancies. The mechanism of action involves the inhibition of negative regulators of immune activation, which results in many patients developing immune-related adverse events (irAEs) including endocrinopathies, pneumonitis, colitis, hepatitis and dermatologic events. Dermatologic irAEs include maculopapular rash, pruritus, vitiligo, blistering disorders, mucocutaneous lichenoid eruptions, rosacea, and exacerbation of psoriasis...
December 11, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27891730/reduction-in-psoriasis-related-pruritus-during-biologic-therapy
#11
L Lazzeri, L Pescitelli, L Tripo, F Ricceri, F Prignano
No abstract text is available yet for this article.
November 27, 2016: Dermatologic Therapy
https://www.readbyqxmd.com/read/27819713/impairment-of-sexual-life-in-3-485-dermatological-outpatients-from-a-multicentre-study-in-13-european-countries
#12
Francesca Sampogna, Damiano Abeni, Uwe Gieler, Lucía Tomas-Aragones, Lars Lien, Géraldine Titeca, Gregor B E Jemec, Laurent Misery, Csanád Szabó, M Dennis Linder, Andrea W M Evers, Jon Anders Halvorsen, Flora Balieva, Jacek C Szepietowski, Dmitry V Romanov, Servando E Marron, Ilknur K Altunay, Andrew Y Finlay, Sam S Salek, Jörg Kupfer, Florence Dalgard
Skin conditions may have a strong impact on patients' sexual life, and thus influence personal relationships. Sexual issues are difficult to discuss directly in clinical practice, and a mediated instrument may be useful to capture such information. In this study item 9 of the Dermatology Life Quality Index was used to collect information on sexual impact of several skin conditions in 13 European countries. Among 3,485 patients, 23.1% reported sexual problems. The impairment was particularly high in patients with hidradenitis suppurativa, prurigo, blistering disorders, psoriasis, urticaria, eczema, infections of the skin, or pruritus...
November 7, 2016: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/27747909/six-years-experience-of-grenz-ray-therapy-for-the-treatment-of-inflammatory-skin-conditions
#13
L Fenton, R S Dawe
BACKGROUND: In 2008, Ninewells Hospital became the first centre in the UK to offer grenz rays as a treatment for inflammatory dermatoses. Since then, 122 courses have been administered for the following conditions; scalp psoriasis (n = 36), nail dystrophies (n = 27), hyperkeratotic eczema/psoriasis (n = 22), palmoplantar pustulosis (n = 9), perianal pruritus (n = 9), warts (n = 4) and other conditions (n = 15). AIM: To review all patients who received grenz rays in order to determine which conditions have been treated successfully and to estimate remission times...
December 2016: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/27716172/treatment-of-plaque-psoriasis-with-an-ointment-formulation-of-the-janus-kinase-inhibitor-tofacitinib-a-phase-2b-randomized-clinical-trial
#14
Kim A Papp, Robert Bissonnette, Melinda Gooderham, Steven R Feldman, Lars Iversen, Jennifer Soung, Zoe Draelos, Carla Mamolo, Vivek Purohit, Cunshan Wang, William C Ports
BACKGROUND: Most psoriasis patients have mild to moderate disease, commonly treated topically. Current topical agents have limited efficacy and undesirable side effects associated with long-term use. Tofacitinib is a small molecule Janus kinase inhibitor investigated for the topical treatment of psoriasis. METHODS: This was a 12-week, randomized, double-blind, parallel-group, vehicle-controlled Phase 2b study of tofacitinib ointment (2 % and 1 %) applied once (QD) or twice (BID) daily in adults with mild to moderate plaque psoriasis...
October 3, 2016: BMC Dermatology
https://www.readbyqxmd.com/read/27692733/tofacitinib-improves-pruritus-and-health-related-quality-of-life-up-to-52%C3%A2-weeks-results-from-2-randomized-phase-iii-trials-in-patients-with-moderate-to-severe-plaque-psoriasis
#15
RANDOMIZED CONTROLLED TRIAL
Steven R Feldman, Diamant Thaçi, Melinda Gooderham, Matthias Augustin, Claudia de la Cruz, Lotus Mallbris, Marjorie Buonanno, Svitlana Tatulych, Mandeep Kaur, Shuping Lan, Hernan Valdez, Carla Mamolo
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that improves clinical measures of psoriasis. OBJECTIVE: We sought to assess patient-reported outcomes in tofacitinib-treated patients with moderate to severe plaque psoriasis over 52 weeks. METHODS: In 2 identical, phase III studies (Oral treatment for Psoriasis Trial Pivotal 1 [NCT01276639], n = 901, and Pivotal 2 [NCT01309737], n = 960), patients were randomized 2:2:1 to receive 5 or 10 mg of tofacitinib or placebo, twice daily...
December 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27686401/relationships-among-plasma-granzyme-b-level-pruritus-and-dermatitis-in-patients-with-atopic-dermatitis
#16
Yayoi Kamata, Utako Kimura, Hironori Matsuda, Suhandy Tengara, Atsuko Kamo, Yoshie Umehara, Kyoichi Iizumi, Hiroaki Kawasaki, Yasushi Suga, Hideoki Ogawa, Mitsutoshi Tominaga, Kenji Takamori
BACKGROUND: Atopic dermatitis (AD) is a multifactorial inflammatory skin disease characterized by skin barrier dysfunction, allergic inflammation and intractable pruritus resistant to conventional antipruritic treatments, including H1-antihistamines. Granzymes (Gzms) are a family of serine proteases expressed by cytotoxic T lymphocytes and natural killer cells that have been shown to modulate inflammation. However, the relationship between Gzms and pathology in AD remains unclear. OBJECTIVE: This study assessed the correlation between plasma GzmB levels and severity of pruritus and dermatitis, in AD patients...
December 2016: Journal of Dermatological Science
https://www.readbyqxmd.com/read/27672693/pruritus-since-childhood
#17
Andrea Richardson, Richard P Usatine
The itchy rash had been previously diagnosed as psoriasis. But treatment provided minimal relief. So what was causing the itch?
September 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/27660843/severe-pruritus-%C3%A2-crusted-lesions-affecting-face-extremities-and-trunk-%C3%A2-hepatitis-c-virus-carrier-%C3%A2-dx
#18
Tuğba Kevser Uzunçakmak, Ayşe Serap Karadağ, Şeyma Özkanlı, Ebru Itır Zemheri, Mukaddes Kavala, Necmettin Akdeniz
The patient had visited various clinics for her complaints and was diagnosed as having contact dermatitis and senile pruritus. She was prescribed topical mometasone furoate and moisturizers. After 6 months of using this therapy, widespread grey-white plaques and minimal excoriation appeared on her face, scalp, and trunk. This was diagnosed as psoriasis, and the patient was prescribed topical corticosteroids, which she used for 9 months until she came to our clinic.
August 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/27649664/pruritus-in-selected-dermatoses
#19
K Olek-Hrab, M Hrab, J Szyfter-Harris, Z Adamski
Pruritus is a natural defence mechanism of the body and creates the scratch reflex as a defensive reaction to potentially dangerous environmental factors. Together with pain, pruritus is a type of superficial sensory experience. Pruritus is a symptom often experienced both in healthy subjects and in those who have symptoms of a disease. In dermatology, pruritus is a frequent symptom associated with a number of dermatoses and is sometimes an auxiliary factor in the diagnostic process. Apart from histamine, the most popular pruritus mediators include tryptase, endothelins, substance P, bradykinin, prostaglandins and acetylcholine...
September 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27578088/itch-management-in-the-elderly
#20
REVIEW
Tabi Anika Leslie
Itch is a common symptom in the elderly population over 65 years old, and is often a chronic condition lasting more than 6 weeks. As in all age groups, but especially in the elderly, there can be a significant effect on the general health status and quality of life, with impaired daily activities and lack of sleep, which can also lead in some cases to depression or anxiety. The cause of chronic itch in the elderly is often multifactorial due to physiological changes in the aging skin, including impaired skin barrier function, and also due to decline in immunological (immunosenescence), neurological, and psychological changes associated with age...
2016: Current Problems in Dermatology
keyword
keyword
14346
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"